In a bid to aid the ongoing effort to develop effective treatments, and ultimately a preventative vaccine, for Zika infection, Future Science Group is making a collection of relevant articles from the journals Future Microbiology and Future Virology freely available via their website.
The Zika virus is a mosquito-borne flavivirus, capable of infecting humans, and which has emerged in recent years as a serious threat to human health. While Zika infection generally causes no-to-mild symptoms in those it infects, it has been potentially linked with neurological conditions such as Guillain-Barré syndrome in adults, and microcephaly, severe brain malformations and other birth defects in instances where Zika virus is believed to have been transmitted from a mother to her unborn fetus.
There are currently no specific treatments for Zika infection (beyond managing symptoms), and no preventative vaccine is yet available.
To download these articles, please visit: http://www.
If you are interested in submitting your own research to Future Microbiology and Future Virology, please contact the Editorial Director, Laura Dormer (firstname.lastname@example.org).
About Future Microbiology & Future Virology
Launched in 2006, the journals Future Microbiology and Future Virology are part of the Future Medicine journal collection. Future Microbiology (impact factor: 3.637) is a MEDLINE-indexed journal with forward-looking focus, covering numerous medical microbiological areas, with an international Editorial Board headed by Senior Editors Professor Richard A Calderone (Georgetown University, WA, USA) and Professor B. Brett Finlay (University of British Columbia, Canada). Future Virology (impact factor: 0.886) features the latest updates in virology, infectious disease and immunology analysis, with an international Editorial Board headed by Editor-in-Chief Mark Wainberg (McGill AIDS Centre, Canada).
About Future Science Group
Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological, and scientific research. FSG's portfolio includes two imprints, Future Science and Future Medicine. In addition to this core publishing business FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine.
The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards. http://www.